Mill Capital Management LLC Invests $9.85 Million in Boston Scientific Corporation $BSX

Posted by Francis Steltz on Aug 15th, 2026

Boston Scientific logo Mill Capital Management LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 230,815 shares of the medical equipment provider’s stock, valued at approximately $9,851,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the 4th quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Boston Scientific in the 1st quarter worth $28,000. Finally, Sfam LLC purchased a new position in Boston Scientific during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Royal Bank Of Canada reduced their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Piper Sandler restated an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research note on Friday, June 12th. Needham & Company LLC cut their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Finally, TD Cowen decreased their price objective on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Get Our Latest Stock Report on BSX

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Boston Scientific Trading Up 0.1%

Shares of NYSE:BSX opened at $51.77 on Friday. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a market cap of $75.02 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.13 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $46.06 and a 200-day moving average price of $59.35.

Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has authorized a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.